Lesson
Connect Cortisol Physiology to Drug Action
Systemic glucocorticoids act through intracellular receptors while also suppressing the HPA axis that normally regulates cortisol. Both actions matter from the first dose through eventual discontinuation.
- CRH and ACTH
- Intracellular receptor
- Gene transcription
- Negative feedback
- Local exposure
The hypothalamus and pituitary drive adrenal cortisol production.
The activated receptor changes inflammatory and metabolic gene expression.
Cortisol and exogenous drug suppress upstream CRH and ACTH release.
Trace the HPA axis
Hypothalamic CRH stimulates pituitary ACTH, which stimulates adrenal cortisol. Cortisol then limits CRH and ACTH through negative feedback. Sustained exogenous glucocorticoid exposure can suppress the entire upstream signal. Physiologic replacement and supraphysiologic anti-inflammatory treatment must remain distinct clinical purposes.
Enter the cell and change transcription
The glucocorticoid receptor is intracellular. The activated complex changes expression of inflammatory and metabolic genes, while rapid non-genomic effects also occur. Biologic action can therefore outlast the plasma half-life.
Separate glucocorticoid from mineralocorticoid effects
Agents differ in anti-inflammatory potency, biologic duration, and sodium-retaining activity. Equivalent anti-inflammatory doses do not produce identical fluid, electrolyte, or HPA effects.
Count every route
Oral and intravenous therapy usually creates obvious systemic exposure. Inhaled, topical, injected, ophthalmic, and locally acting formulations can also contribute, especially at high dose, with repeated use, or during a pharmacokinetic interaction.
Quick check
Checking for saved practice…
Lesson
Read Structure as a Clinical Design Map
Corticosteroid structure controls receptor recognition, metabolic activation, tissue exposure, formulation, and the balance between glucocorticoid and mineralocorticoid activity. Structural rules explain patterns, but the labeled product still governs clinical use.
- Steroid nucleus
- Receptor-binding groups
- Prednisone activation
- Ester design
- C1-C2 unsaturation
- C9, C16, and C6 substitution
The active 11 beta hydroxyl pattern distinguishes prednisolone from its prednisone prodrug.
Unsaturation, halogenation, and methyl or hydroxyl groups alter potency and salt retention.
Ester design changes solubility, hydrolysis, onset, route, and depot duration.
Recognize the corticosteroid scaffold
The fused steroid nucleus positions the A-ring 3-keto group, C11 oxygen function, C17 side chain, and C21 oxygen function in a three-dimensional pattern recognized by corticosteroid receptors. Changing one position can affect receptor binding, metabolism, selectivity, solubility, or duration.
Preserve the receptor-binding pattern
The A-ring 3-keto and 4-ene pattern, C11 beta hydroxyl in active glucocorticoids, C17 alpha hydroxyl, C20 carbonyl, and C21 hydroxyl contribute to activity. Cortisone and prednisone carry an 11-keto group and require reduction to hydrocortisone and prednisolone, respectively, for full glucocorticoid activity.
Use unsaturation and halogenation deliberately
Adding a C1-C2 double bond, as in prednisolone, increases glucocorticoid activity relative to hydrocortisone and tends to reduce mineralocorticoid activity. C9 fluorination can increase both glucocorticoid and mineralocorticoid potency, so other substitutions are often needed to restore selectivity.
Control selectivity with C16 and C6 substitution
C16 substitutions do not all have the same effect: methyl groups can favor glucocorticoid selectivity, whereas a polar C16 hydroxyl can reduce glucocorticoid potency. Judge the complete molecule rather than treating every C16 group as a potency increase. A C6 methyl group, as in methylprednisolone, increases glucocorticoid activity and reduces clinically meaningful salt-retaining activity relative to prednisolone.
Treat esters as formulation tools
Esterification can change solubility, absorption, depot behavior, and hydrolysis rate. Hydrophilic phosphate or succinate salts support rapid aqueous administration, while lipophilic acetate and related esters can prolong local or depot exposure. For example, Solu-Medrol sodium succinate supports IV or IM administration; Depo-Medrol acetate suspension must not be given IV. Verify the exact product and route before administration.
Quick check
Checking for saved practice…
Lesson
Select and Convert Without Losing Context
Potency tables are useful only when they remain attached to biologic duration, route, mineralocorticoid activity, indication, and clinical response.
- Hydrocortisone
- Prednisone
- Methylprednisolone
- Dexamethasone
- Conversion limits
Short acting with meaningful mineralocorticoid activity.
Intermediate acting and converted to active prednisolone.
2024 joint guideline estimate; other tables differ. Long acting with minimal salt retention.
Anchor the common equivalence
Approximate anti-inflammatory equivalents are hydrocortisone 20 mg, cortisone acetate 25 mg, prednisone or prednisolone 5 mg, methylprednisolone or triamcinolone 4 mg, and, in Table 1 of the 2024 joint endocrine guideline, dexamethasone or betamethasone 0.5 mg. Other reference tables differ: RxPrep lists dexamethasone 0.75 mg and betamethasone 0.6 mg. Identify the source and use a consistent table for a calculation; these estimates do not establish exact clinical interchangeability.
Calculate in two steps
Identify the source drug equivalent, determine how many equivalent units are present, then multiply by the target drug equivalent. For example, methylprednisolone 32 mg contains eight 4 mg units and approximates prednisone 40 mg.
Compare biologic duration
Hydrocortisone is short acting, prednisone and methylprednisolone are intermediate acting, and dexamethasone is long acting. Long action can be useful in selected acute conditions but complicates prolonged HPA recovery.
Remember that a table is not the patient
Conversions are estimates. Route, formulation, absorption, hepatic activation of prednisone, tissue response, disease activity, and concurrent medicines can change the observed effect after a switch.
Quick check
Checking for saved practice…
Lesson
Begin With an Exit Strategy
A glucocorticoid order should name the disease, intended benefit, dose, route, duration, reassessment point, and discontinuation plan. A package or memorized taper cannot decide those elements.
- Indication
- Route
- Morning dosing
- Food
- Short course
Define the disease, desired response, and time horizon.
Use the most targeted effective regimen for the shortest necessary duration.
Document when to stop, taper, switch, or add steroid-sparing care.
Write the treatment question
State what the glucocorticoid must accomplish and how quickly. Replacement therapy, acute anti-inflammatory rescue, chronic immunosuppression, cerebral edema, and fetal maturation use different drugs, doses, and schedules.
Choose the narrowest effective exposure
Use local therapy when it can adequately treat the site, but keep systemic absorption in view. When systemic therapy is required, select the least exposure that controls the disease and plan steroid-sparing treatment when appropriate.
Make administration usable
When the regimen permits, a single morning dose better follows endogenous rhythm and may reduce insomnia. Oral doses are often taken with food to reduce dyspepsia. Product directions and disease-specific schedules remain authoritative.
Apply the current short-course rule
The 2024 Endocrine Society guideline suggests no adrenal taper or testing after systemic treatment shorter than three to four weeks when the underlying condition permits discontinuation. A disease-specific taper may still be needed to prevent recurrence.
Quick check
Checking for saved practice…
Lesson
Recognize Suppression Before the Final Dose
Adrenal suppression is not defined by the same threshold used for live-vaccine safety. Risk emerges from dose, duration, potency, route, repeated exposure, cushingoid features, and interactions.
- Physiologic dose
- Duration
- Cushingoid features
- Multiple routes
- Interactions
Prednisone above about 4 to 6 mg daily can become relevant with duration.
Sustained exposure makes endogenous recovery a discontinuation concern.
Multiple products and CYP3A4 inhibition can raise cumulative exposure.
Use the current risk frame
The 2024 guideline expects oral exposure to pose adrenal risk when it exceeds both three to four weeks and physiologic equivalence, about hydrocortisone 15 to 25 mg or prednisone 4 to 6 mg daily. Individual risk still varies.
Do not borrow the vaccine threshold
In people weighing more than 10 kg, prednisone 20 mg daily for at least 14 days is a CDC high-dose threshold for live-vaccine safety. It is not the threshold for HPA suppression, bone risk, glucose toxicity, or every other steroid decision.
Read the phenotype
Facial rounding, proximal weakness, skin fragility, bruising, striae, hypertension, hyperglycemia, and weight change can reveal sustained systemic exposure. With current or prior glucocorticoid exposure and exogenous Cushing features, the 2024 guideline advises assuming glucocorticoid-induced adrenal insufficiency.
Find hidden exposure
Ask about injections, inhalers, nasal products, creams, eye drops, and recent procedures. Strong CYP3A4 inhibitors can increase exposure from susceptible formulations and turn an apparently local regimen into systemic toxicity.
Quick check
Checking for saved practice…
Lesson
Taper the Disease First, Then the Axis
A taper must protect control of the original disease and the recovering HPA axis. Those objectives dominate at different points in the dose range.
- Disease control
- Supraphysiologic dose
- Physiologic dose
- Withdrawal
- Morning cortisol
The original condition must no longer require the current dose.
Supraphysiologic doses often permit faster initial reductions.
Near physiologic dosing, withdrawal and HPA recovery guide the pace.
Confirm that a taper is appropriate
Begin a long-term taper only when the underlying disease is controlled and glucocorticoid therapy is no longer required. Coordinate disease-modifying treatment before using the calendar as the primary driver.
Change pace with the dose
Larger, faster reductions can be reasonable at high supraphysiologic doses. Use smaller, slower decrements near prednisone 4 to 6 mg equivalent, where withdrawal and adrenal recovery become more important.
Build the symptom differential
Fatigue, weakness, pain, nausea, low mood, and poor function can reflect withdrawal syndrome, adrenal insufficiency, or disease recurrence. Timing, vital signs, electrolytes, disease findings, and dose response help separate them.
Use morning cortisol when needed
When confirmation is desired near physiologic dosing, obtain recovery cortisol at 8 to 9 AM after a clinician-directed hold of at least 24 hours for appropriate shorter-acting glucocorticoids. Dexamethasone needs a separate plan rather than an assumed 24-hour washout. Do not withhold necessary stress coverage during illness to obtain a test. Morning cortisol is the preferred first recovery test. Above 10 mcg/dL supports recovery, 5 to 10 requires continued physiologic coverage and later reassessment, and below 5 supports continued coverage with repeat testing. Routine dynamic testing is not recommended during the taper. Seek endocrinology evaluation if recovery has not occurred after one year at physiologic dosing, or with a history of adrenal crisis.
Quick check
Checking for saved practice…
Lesson
Protect the Patient During Physiologic Stress
Current or recent users without confirmed HPA recovery need a route-appropriate stress plan. Hemodynamic instability, vomiting, and inability to absorb oral therapy demand urgent action.
- Minor stress
- Major stress
- Oral absorption
- Adrenal crisis
- Emergency identity
Use when stress is limited and oral absorption remains reliable.
Use for major illness, general or regional anesthesia, instability, or inability to take oral therapy.
Give parenteral glucocorticoid and fluids without waiting for laboratory certainty.
Match coverage to the stress
Minor stress with reliable oral intake can use oral glucocorticoid coverage. An existing dose may already provide adequate coverage; do not automatically add the same extra dose to every regimen. Major illness, procedures under general or regional anesthesia, prolonged inability to take oral therapy, hemodynamic instability, or prolonged vomiting or diarrhea requires parenteral coverage.
Recognize the crisis pattern
Consider adrenal crisis in an at-risk patient with hypotension, volume depletion, vomiting, abdominal symptoms, weakness, confusion, hypoglycemia or hyponatremia. Aldosterone is generally preserved in glucocorticoid-induced insufficiency, so hyperkalemia is not a typical consequence of this mechanism; assess other causes if it occurs. Presentation can be incomplete.
Treat before proof
Give parenteral glucocorticoid and fluid resuscitation promptly when crisis is suspected. Obtain diagnostic samples when feasible, but do not delay treatment while waiting for cortisol results.
Make the plan portable
Provide written sick-day instructions, current dose and taper information, medical alert identification, and emergency contact guidance. Glucocorticoid-induced adrenal insufficiency does not routinely require fludrocortisone.
Quick check
Checking for saved practice…
Lesson
Monitor the Toxicity Pattern, Not a Generic List
Glucocorticoid toxicity has timing, agent, and patient patterns. Monitoring should anticipate when glucose, fluid, mood, gastrointestinal, and cardiovascular effects are most likely to appear.
- Hyperglycemia
- Blood pressure
- Fluid retention
- Neuropsychiatric effects
- Gastrointestinal risk
Morning prednisone often drives afternoon and evening hyperglycemia.
Insomnia, mood change, mania, delirium, and psychosis require active surveillance.
NSAIDs, anticoagulants, history, and illness change the protection plan.
Look beyond fasting glucose
Morning prednisone often produces rising afternoon and evening glucose while fasting values remain near normal. The 2026 ADA standard matches glucose checks and insulin strategy to steroid duration, dose timing, nutrition, and dose changes.
Protect cardiovascular stability
Monitor weight, edema, blood pressure, sodium, potassium, and heart-failure symptoms. Equivalent anti-inflammatory doses can still differ in mineralocorticoid activity and biologic duration.
Prepare for psychiatric change
Counsel about sleep disturbance, agitation, depression, mania, delirium, and psychosis. Establish a baseline and arrange urgent assessment for severe behavior change, suicidality, or loss of judgment.
Layer gastrointestinal risk
Food can reduce dyspepsia but does not eliminate bleeding. Review NSAIDs, anticoagulants, antiplatelets, prior ulcer disease, alcohol, age, and critical illness before deciding whether gastroprotection is indicated.
Quick check
Checking for saved practice…
Lesson
Plan for Infection and Vaccination
Infection risk and vaccine response change before a patient necessarily feels a complication. Prevention must begin near the start of sustained therapy.
- Muted infection
- Live vaccine
- Non-live vaccine
- Dose threshold
- Timing
Immunosuppression can blunt fever while infection progresses.
Dose and duration determine deferral and the post-treatment waiting period.
Give indicated vaccines while recognizing that effectiveness can be reduced.
Expect muted infection signals
Systemic glucocorticoids can raise infection risk and blunt fever or inflammatory findings. Teach patients to report new focal symptoms, weakness, confusion, or deterioration rather than waiting for a high temperature.
Check infection risk before prolonged immunosuppression
Medrol labeling calls for hepatitis B screening before immunosuppressive treatment and expert advice when infection is identified. Assess tuberculosis history and latent-infection management. Known or suspected Strongyloides requires particular caution because steroids can trigger dangerous dissemination. Systemic fungal infection also requires urgent product-specific review.
Act after exposure
A nonimmune patient receiving immunosuppressive therapy should report measles or varicella exposure promptly for assessment of postexposure prophylaxis. Do not wait for symptoms or try to solve the exposure by giving a live vaccine during high-dose therapy.
Use the CDC live-vaccine threshold correctly
At least 20 mg prednisone equivalent daily in people weighing more than 10 kg, or at least 2 mg/kg daily, for at least 14 consecutive days is considered high-dose systemic therapy for live-vaccine decisions. Defer live vaccination for at least one month after it stops.
Keep non-live vaccines in view
Non-live vaccines are safe during altered immunocompetence, though response can be reduced. Give indicated vaccines before immunosuppression when practical, and follow disease-specific guidance instead of withholding everything.
Time prevention before exposure
When possible, give needed live vaccines at least four weeks and non-live vaccines at least two weeks before immunosuppressive therapy. Do not delay urgently needed disease treatment solely because a vaccine was recently given.
Quick check
Checking for saved practice…
Lesson
Protect Bone, Muscle, Eyes, Skin, and Growth
Skeletal and tissue toxicity can progress quietly. Early risk assessment and longitudinal examination prevent a chronic regimen from becoming a late surprise.
- Fracture risk
- Bone density
- Calcium and vitamin D
- Myopathy
- Growth and eyes
Duration, dose, age, history, density, and falls shape prevention.
Proximal myopathy and skin fragility can emerge during sustained exposure.
Monitor ocular effects and pediatric growth before loss becomes obvious.
Assess bone risk early
For adults starting or continuing at least 2.5 mg prednisone equivalent for more than three months, current ACR guidance supports prompt fracture-risk assessment. Age, prior fracture, bone density, falls, dose, duration, and other factors guide prevention or treatment.
Build the foundation
Review calcium and vitamin D intake, weight-bearing and resistance activity, fall risk, smoking, alcohol, hypogonadism, and other secondary causes. Lifestyle measures support but do not replace pharmacotherapy when fracture risk warrants treatment.
Look for proximal myopathy and skin change
Ask about difficulty rising, climbing stairs, lifting, bruising, striae, and slow wound healing. Distinguish steroid myopathy from inflammatory weakness, deconditioning, neuropathy, and critical illness.
Monitor eyes and growth
Review cataract or glaucoma symptoms and arrange examination according to exposure and risk. Track linear growth in children and adolescents, then reconsider cumulative dose and steroid-sparing options when growth falters.
Quick check
Checking for saved practice…
Lesson
Make Cumulative Exposure Visible
Long-term safety depends on a shared record that connects every route, interaction, adverse effect, monitoring result, vaccine, bone plan, taper step, and stress instruction.
- Growth
- Eye toxicity
- Myopathy
- CYP3A4
- Transitions
Include tablets, injections, inhalers, creams, eye products, and procedures.
Track CYP3A4 changes, glucose, bone, eyes, muscle, skin, and growth.
Carry the indication, taper, stress instructions, and next decision across care.
Monitor the systems that change slowly
Review cataract or glaucoma symptoms, proximal strength, skin fragility, wound healing, weight, and pediatric growth. Do not let glucose and blood pressure become the only monitored outcomes.
Reconcile pharmacokinetic interactions
Strong CYP3A4 inhibitors can increase exposure to susceptible glucocorticoids, while strong inducers can reduce effect. Plan for both initiation and discontinuation of the interacting medicine.
Track cumulative exposure
Combine oral, intravenous, inhaled, injected, topical, nasal, and ophthalmic products in one timeline. Record recent procedures and dose packs that may not appear in the active medication list.
Build one authoritative handoff
Document indication, agent, route, equivalent dose, duration, taper status, monitoring, vaccine plan, bone plan, glucose plan, adrenal-risk status, stress instructions, and the clinician responsible for the next decision.
Use current reproductive labeling
Pregnancy and lactation decisions use current narrative labeling, maternal disease risk, dose, duration, exposure, and suitable alternatives. Retired pregnancy letters and blanket class prohibitions do not replace an individualized risk comparison.
Quick check
Checking for saved practice…
Module practice
Check the connections.
Each attempt draws 10 questions from the complete 48 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Core source material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.
- Hobson AD, et al. RSC Medicinal Chemistry (2024): steroid oxygen groups and glucocorticoid receptor binding; author manuscript.
- DailyMed. Fluticasone propionate HFA: CYP3A4 inhibitor interactions and adrenal suppression.
- Endotext. Glucocorticoid Therapy and Adrenal Suppression (2018): mechanism and structural pharmacology; current taper guidance is cited separately.
- DailyMed. Solu-Medrol sodium succinate: formulation and route labeling.
- DailyMed. Depo-Medrol acetate suspension: not for intravenous use.
- ACR 2022 GIOP guideline summary, revised July 2023
- Endocrine Society and European Society of Endocrinology. Glucocorticoid-Induced Adrenal Insufficiency Guideline Resources.
- Beuschlein F, et al. Diagnosis and Therapy of Glucocorticoid-Induced Adrenal Insufficiency. JCEM. 2024.
- CDC. Altered Immunocompetence: Corticosteroids and Vaccination.
- American College of Rheumatology. 2022 Guideline for Glucocorticoid-Induced Osteoporosis.
- American College of Rheumatology. 2022 Vaccinations Guideline.
- American Diabetes Association. Diabetes Care in the Hospital: Standards of Care in Diabetes 2026.
- DailyMed. Prednisone Tablets Prescribing Information.
- DailyMed. Medrol Methylprednisolone Tablets Prescribing Information.
- DailyMed. Dexamethasone Tablets Prescribing Information.
- Endocrine Society. Primary Adrenal Insufficiency Guideline Resources.